PRESS-RELEASE ·Filed May 15, 2026
Press release · Earnings
Actionable Insight • Neutral
This filing is purely procedural — no trading signal. Monitor for future clinical trial results or regulatory updates on BOTRESO® for potential catalysts.
Final — all horizons settled through T+60d
MENS ▲ +4.48% at T+60d
NEUTRAL call +4.48% · α vs SPY -0.04% · entry $2.01 → $2.10
T+1d
-2.99%
call -2.99% · α -2.92%
$1.95
settled 5mo ago
T+5d
+6.97%
call +6.97% · α +6.00%
$2.15
settled 5mo ago
T+20d
-21.39%
call -21.39% · α -23.51%
$1.58
settled 4mo ago
T+60d
+4.48%
call +4.48% · α -0.04%
$2.10
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Jyong Biotech filed its FY2025 annual report on Form 20-F, a routine regulatory milestone. The press release contains no financial results, guidance, or material business updates — it is purely an administrative filing notification.
Key Facts
- Filed FY2025 annual report on Form 20-F with the SEC on May 14, 2026
- No financial results, earnings, or guidance disclosed in the press release
- Company is a pre-commercialization biotech focused on plant-derived therapeutics for urinary system diseases
- Lead candidate BOTRESO® is in clinical development; no revenue reported
Financial Impact
No financial data disclosed — filing is administrative only
Risk Factors
- No revenue or near-term commercialization timeline disclosed
- Clinical-stage biotech with binary pipeline risk
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295834 |
2 reports for MENS
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
May 15, 2026 23w ago | Press Release | $2.01 $2.10 | ▲ +4.48% | ▼ −0.04% | $1.87 (−6.97%) |
May 14, 2026 23w ago | 20-F | $2.01 $2.10 | ▼ −4.48% | ▲ +0.04% | $1.87 (+6.97%) |
Showing 2 of 2
US Market Status
Market Open — Closes in 43m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers